Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06781983 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
A Phase 1 study of Advanced or Metastatic Solid Tumors, sponsored by Innate Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 145
- Enrollment target
- 7
- Study locations
NCT06781983 is a Phase 1 study of Advanced or Metastatic Solid Tumors that is actively recruiting participants, run by Innate Pharma. The registered enrollment target is 145 participants, below the 229-participant average among 19 other Advanced or Metastatic Solid Tumors trials with a reported enrollment target (37% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT06781983, a Phase 1 study of Advanced or Metastatic Solid Tumors, is actively recruiting participants, sponsored by Innate Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 145 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are known to express Nectin-4
Conditions Studied
Interventions
- DRUG IPH4502
Study Locations (7)
Other
- Centre Léon Bérard - Lyon
- Gustave Roussy Cancer Institute - Villejuif
Massachusetts
- Massachusetts General Hospital - Boston - Boston
New Jersey
- John Theurer Cancer Center - Hackensack
New York
- Mount Sinai Tisch Cancer Center - New York
Texas
- NEXT Oncology - Dallas - Dallas
Virginia
- NEXT Oncology - Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2025-01-24 |
| Est. Completion | 2029-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06781983
The ClinicalTrials.gov registry entry for NCT06781983 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 229-participant average among 19 other Advanced or Metastatic Solid Tumors trials with a reported enrollment target (37% lower). The listed sponsor is Innate Pharma, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced or Metastatic Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which IPH4502 is the first listed.
NCT06781983 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Other, Massachusetts, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06781983 about?
NCT06781983 is a clinical study titled "Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors". This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are known to express Nectin-4
What is the current status of trial NCT06781983?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 145 participants. The study started on 2025-01-24. Estimated completion is 2029-04.
What conditions does trial NCT06781983 study?
This clinical trial studies the following conditions: Advanced or Metastatic Solid Tumors.
What interventions are being tested in trial NCT06781983?
The interventions under investigation include: IPH4502 (DRUG).
Who is sponsoring clinical trial NCT06781983?
This trial is sponsored by Innate Pharma, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06781983 being conducted?
This trial has 7 study locations across Massachusetts, New Jersey, New York, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced or Metastatic Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
RECRUITING · Phase 1
-
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.